Exploring regulation of tumor immune microenvironment and immune cells by traditional Chinese medicine based on theory of "yin⁃yang self⁃harmony"

LI Nana; MA Zhenhui; ZHANG Ying; WANG Linxuan; ZHANG Yuxin; LI Honglin

doi:10.16305/j.1007-1334.2024.z20240519003

您当前的位置：

首页 >

文章列表页 >

Exploring regulation of tumor immune microenvironment and immune cells by traditional Chinese medicine based on theory of "yin⁃yang self⁃harmony"

更新时间：2024-12-23

- Exploring regulation of tumor immune microenvironment and immune cells by traditional Chinese medicine based on theory of "yin⁃yang self⁃harmony"
- Shanghai Journal of Traditional Chinese Medicine Vol. 58, Issue 12, Pages: 22-27(2024)
- 作者机构：
  
  1.河南中医药大学第二临床医学院（河南郑州 450002）
  2.河南省中医院肿瘤科（河南郑州 450003）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2024.z20240519003
  CLC：
- Published：10 December 2024，
  
  Received：19 May 2024，
- 稿件说明：
移动端阅览
李娜娜,马祯慧,张颖,等.基于“阴阳自和”理论探析中医药对肿瘤免疫微环境及其免疫细胞的调控作用[J].上海中医药杂志,2024,58(12):22-27.

LI Nana,MA Zhenhui,ZHANG Ying,et al.Exploring regulation of tumor immune microenvironment and immune cells by traditional Chinese medicine based on theory of "yin⁃yang self⁃harmony"[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):22-27.
李娜娜,马祯慧,张颖,等.基于“阴阳自和”理论探析中医药对肿瘤免疫微环境及其免疫细胞的调控作用[J].上海中医药杂志,2024,58(12):22-27. DOI： 10.16305/j.1007-1334.2024.z20240519003.

LI Nana,MA Zhenhui,ZHANG Ying,et al.Exploring regulation of tumor immune microenvironment and immune cells by traditional Chinese medicine based on theory of "yin⁃yang self⁃harmony"[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):22-27. DOI： 10.16305/j.1007-1334.2024.z20240519003.

摘要

肿瘤免疫微环境（TIME）中存在大量免疫细胞，包括肿瘤相关中性粒细胞（TANs）、肿瘤相关巨噬细胞（TAMs）、调节性T细胞（Treg）和树突状细胞（DCs）等，正常生理状态下人体的免疫细胞维持着动态平衡，在机体免疫应答、免疫维持方面发挥着重要作用。肿瘤免疫治疗即靶向TIME的免疫抑制细胞，使人体自身免疫系统恢复其免疫原性。不论是机体正常的免疫应答机制，还是现代肿瘤免疫治疗机制都与中医“阴阳自和”理论高度相似。探究肿瘤免疫细胞失衡与中医“阴阳自和”的相关性，可为阴阳理论指导下的中医药调控免疫细胞恢复免疫循环提供新思路。

Abstract

The tumor immune microenvironment（TIME） contains numerous immune cells， including tumor-associated neutrophils（TANs）， tumor-associated macrophages （TAMs）， regulatory T cells（Tregs）， and dendritic cells（DCs）. Under normal physiological conditions， the human body's immune cells maintain a dynamic balance， playing a critical role in immune responses and homeostasis. Tumor immunotherapy targets the immunosuppressive cells within the TIME to restore the immune system's immunogenicity. Both the body's natural immune response and the mechanisms behind modern tumor immunotherapy share significant parallels with the traditional Chinese medicine（TCM） theory of "yin-yang self-harmony". Investigating the correlation between immune cell imbalance in tumors and the "yin-yang self-harmony" theory in TCM offers a new perspective on how TCM can regulate immune cells to restore immune balance and circulation based on the guidance of yin-yang theory.

关键词

肿瘤微环境免疫调控阴阳自和中医理论中医药疗法

Keywords

tumor microenvironmentimmune regulationyin-yang self-harmonytraditional Chinese medicine theorytraditional Chinese medicine therapy

references

YANG L， WANG Q， HE L， et al. The critical role of tumor microbiome in cancer immunotherapy［J］. Cancer Biol Ther， 2024， 25（1）： 2301801.

张朋.《周易》对阴阳观念的三重表述［J］. 中州学刊， 2023（3）： 131-136.

DAGHER O K， SCHWAB R D， BROOKENS S K， et al. Advances in cancer immunotherapies［J］. Cell， 2023， 186（8）： 1814.

MILLS K H G. IL-17 and IL-17-producing cells in protection versus pathology［J］. Nat Rev Immunol， 2023， 23（1）： 38-54.

PAN Y， YANG W， TANG B， et al. The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment［J］. Front Immunol， 2023， 14： 1192303.

ITAHASHI K， IRIE T， NISHIKAWA H. Regulatory T-cell development in the tumor microenvironment［J］. Eur J Immunol， 2022， 52（8）： 1216-1227.

ZHENG X， DONG L， WANG K， et al. MiR-21 participates in the PD-1/PD-L1 pathway-mediated imbalance of Th17/Treg cells in patients after gastric cancer resection［J］. Ann Surg Oncol， 2019， 26（3）： 884-893.

BUI I， BONAVIDA B. Polarization of M2 tumor-associated macrophages （TAMs） in cancer immunotherapy［J］. Crit Rev Oncog， 2024， 29（4）： 75-95.

MA R Y， BLACK A， QIAN B Z， et al. Macrophage diversity in cancer revisited in the era of single-cell omics［J］. Trends Immunol， 2022， 43（7）： 546-563.

MULDER K， PATEL A A， KONG W T， et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease［J］. Immunity， 2021， 54（8）： 1883-1900.

JUNG M， BONAVIDA B. Immune evasion in cancer is regulated by tumor-asociated macrophages （TAMs）： targeting TAMs［J］. Crit Rev Oncog， 2024， 29（4）： 1-17.

ROGOZYNSKI N P， DIXON B. The Th1/Th2 paradigm： A misrepresentation of helper T cell plasticity［J］. Immunol Lett， 2024， 268： 106870.

SPEISER D E， CHIJIOKE O， SCHAEUBLE K， et al. CD4+ T cells in cancer［J］. Nat Cancer， 2023， 4（3）： 317-329.

FRAFJORD A， BUER L， HAMMARSTRÖM C， et al. The immune landscape of human primary lung tumors is Th2 skewed［J］. Front Immunol， 2021， 12： 764596.

LEE Y H， TSAI K W， LU K C， et al. Cancer as a dysfunctional immune disorder： pro-tumor TH1-like immune response and anti-tumor THαβ immune response based on the complete updated framework of host immunological pathways［J］. Biomedicines， 2022， 10（10）： 2497.

LIU G， LIU F. Bach2： A key regulator in Th2-related immune cells and Th2 immune response［J］. J Immunol Res， 2022， 2022： 2814510.

BASU A， RAMAMOORTHI G， ALBERT G， et al. Differentiation and regulation of T cells： a balancing act for cancer immunotherapy［J］. Front Immunol， 2021， 12： 669474.

XIAO Y， HUANG Y， JIANG J， et al. Identification of the prognostic value of Th1/Th2 ratio and a novel prognostic signature in basal-like breast cancer［J］. Hereditas， 2023， 160（1）： 2.

CHEN Y， SUN J， LUO Y， et al. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer［J］. J Transl Med， 2022， 20（1）： 615.

JI T， LI H. T-helper cells and their cytokines in pathogenesis and treatment of asthma［J］. Front Immunol， 2023， 14： 1149203.

AWASTHI D， SARODE A. Neutrophils at the crossroads： Unraveling the multifaceted role in the tumor microenvironment［J］. Int J Mol Sci， 2024， 25（5）： 2929.

VILLAR V H， SUBOTIČKI T， ĐIKIĆ D， et al. Transforming growth factor-β1 in cancer immunology： Opportunities for immunotherapy［J］. Adv Exp Med Biol， 2023， 1408： 309-328.

GEH D， LESLIE J， RUMNEY R， et al. Neutrophils as potential therapeutic targets in hepatocellular carcinoma［J］. Nat Rev Gastroenterol Hepatol， 2022， 19（4）： 257‐273.

CHEN X， WANG N， JING C， et al. The TGF-β/MMP9/RAGE axis induces sRAGE secretion by neutrophils and promotes oral carcinogenesis［J］. Biochem Biophys Rep， 2024， 38： 101676.

MURAO A， AZIZ M， WANG P. Neutrophil heterogeneity in sepsis： the role of damage-associated molecular patterns［J］. Shock， 2023， 59（2）： 239-246.

ZHANG J， GU J， WANG X， et al. Engineering and targeting neutrophils for cancer therapy［J］. Adv Mater， 2024， 36（19）： e2310318.

JAILLON S， PONZETTA A， DI MITRI D， et al. Neutrophil diversity and plasticity in tumour progression and therapy［J］. Nat Rev Cancer， 2020， 20（9）： 485-503.

TAUCHER E， TAUCHER V， FINK-NEUBOECK N， et al. Role of tumor-associated neutrophils in the molecular carcinogenesis of the lung［J］. Cancers， 2021， 13（23）： 5972.

ZHENG W， WU J， PENG Y， et al. Tumor-associated neutrophils in colorectal cancer development， progression and immunotherapy［J］. Cancers （Basel）， 2022， 14（19）： 4755.

MASUCCI M T， MINOPOLI M， CARRIERO M V. Tumor associated neutrophils. Their role in tumorigenesis， metastasis， prognosis and therapy［J］. Front Oncol， 2019， 9： 1146.

HILLIGAN K L， RONCHESE F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses［J］. Cell Mol Immunol， 2020， 17（6）： 587-599.

MORANTE-PALACIOS O， FONDELLI F， BALLESTAR E， et al. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases［J］. Trends Immunol， 2021， 42（1）： 59-75.

ARABPOUR M， LEBRERO-FERNANDRZ C， SCHÖN K， et al. ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection［J］. Mucosal Immunol， 2022， 15（4）： 745-761.

SHANG Q， YU X， SUN Q， et al. Polysaccharides regulate Th1/Th2 balance： A new strategy for tumor immunotherapy［J］. Biomed Pharmacother， 2024， 170： 115976.

KIDDANE A T， KIM G D. Anticancer and immunomodulatory effects of polysaccharides［J］. Nutr Cancer， 2021， 73（11-12）： 2219-2231.

WANG X E， WANG Y H， ZHOU Q， et al. Immunomodulatory effect of lentinan on aberrant T subsets and cytokines profile in non-small cell lung cancer patients［J］. Pathol Oncol Res， 2020， 26（1）： 499-505.

HU Q， LIU Y， YU J， et al. The protective effect and antitumor activity of Aconiti Lateralis Radix Praeparata （Fuzi） polysaccharide on cyclophosphamide-induced immunosuppression in H22 tumor-bearing mice［J］. Front Pharmacol， 2023， 14： 1151092.

LUO Y， LIU G， HOU P， et al. Synergism effect of dendrobine on cisplatin in treatment of H1299 by modulating the balance of Treg/Th17［J］. Anticancer Agents Med Chem， 2023， 23（1）： 105-112.

高聚伟，徐凯，冉冉，等. 龙葵碱对肝癌Treg细胞介导的肿瘤免疫逃逸的影响［J］. 中国现代医生， 2021， 59（18）： 35-38.

WAN Q， HUANG J， XIAO Q， et al. Astragalus polysaccharide alleviates ulcerative colitis by regulating the balance of mTh17/mTreg cells through TIGIT/CD155 signaling［J］. Molecules， 2024， 29（1）：241.

吕彩霞，苑晓烨，邵伟华，等. 黄芪多糖对老年晚期胃癌病人外周血中调节性T细胞的影响［J］. 实用老年医学， 2021， 35（6）： 564-567.

LI C， PAN X Y， MA M， et al. Astragalus polysacharin inhibits hepatocellular carcinoma-like phenotypes in a murine HCC model through repression of M2 polarization of tumour-associated macrophages［J］. Pharm Biol， 2021， 59（1）： 1533-1539.

庄晓丹，刘浩恩，陈益超，等. 通阳化气汤加减联合化疗对胃癌患者疾病控制率和CEA、VEGF、Th17/Treg水平的影响［J］. 四川中医， 2022， 40（8）： 94-98.

章震，黄开红，朱林. 六君子汤加减联合肠内营养对老年胃癌术后气血两虚证早期营养状态与免疫功能的影响［J］. 吉林中医药， 2022， 42（9）： 1052-1055.

刘静雯，王瑜，冯媛媛，等. 补肾解毒方调控肿瘤相关巨噬细胞M2极化对大肠癌转移的影响［J］. 中国实验方剂学杂志， 2022， 28（17）： 60-66.

张欣悦，钟融，崔洪蛟，等. 加味四君子汤对小鼠CT26大肠癌移植瘤的抑制作用及肿瘤相关巨噬细胞CD68、CD206蛋白表达的影响［J］. 上海中医药大学学报， 2019， 33（2）：61-65.

HAN S， WANG W， WANG S， et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes［J］. Theranostics， 2021， 11（6）： 2892-2916.

许海柱，邓海滨，陈佩晶，等. 徐振晔从脾肾论治肺癌经验［J］.上海中医药杂志， 2024， 58（6）： 53-56， 81.

李磊，夏宏盛. 阳和益肺汤辅助治疗对肺纤维化患者血清TGF-β， TNF-α水平的影响［J］. 中华保健医学杂志， 2022， 24（4）： 266-269.

李洪霖，董良，郗昱檀，等. 温阳散结汤含药血清通过NF-κB通路调控肿瘤相关巨噬细胞极化对Lewis肺癌的影响［J］. 现代肿瘤医学， 2022， 30（18）： 3257-3264.

LUO N. Advances in targeted immunotherapy in cancers［J］. Int J Mol Sci， 2023， 24（24）： 17475.

NAIMI A， MOHAMMED R N， RAJI A， et al. Tumor immunotherapies by immune checkpoint inhibitors （ICIs）； the pros and cons［J］. Cell Commun Signal， 2022， 20（1）： 44.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Discussion on immune regulation of gastric cancer based on "state target regulation‑positive deficiency toxicity"

Theoretical exploration of intergenerational effects in polycystic ovary syndrome based on latent pathogens

Exploring pathogenesis and treatment of autoimmune diseases from perspective of "transformation of Weiqi into Huaqi"

Modern traditional Chinese doctors' understanding of gastric cancer pathogenesis and innovative treatment approaches

Exploring feasibility of strengthening spleen and nourishing kidney method in regulating intestinal microflora in treatment of systemic lupus erythematosus based on "kidney‑spleen‑intestine axis" theory

Related Author

WU Siyu

SUI Bowen

LI Jing

SUN Chang

ZHAO Shanshan

KUANG Hongying

WANG Ying

SUN Miao

Related Institution

Graduate School of Heilongjiang University of Chinese Medicine

Department of Oncology No.1， The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

First School of Clinical Medicine， Heilongjiang University of Chinese Medicine

Department of Gynecology Ⅱ， The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

Department of Gastroenterology Ⅱ， The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

⁰